WealthTrust Axiom LLC maintained its stake in Eli Lilly and Co. (NYSE:LLY) during the second quarter, Holdings Channel reports. The institutional investor owned 32,648 shares of the company’s stock at the end of the second quarter. Eli Lilly and makes up about 1.0% of WealthTrust Axiom LLC’s investment portfolio, making the stock its 28th largest position. WealthTrust Axiom LLC’s holdings in Eli Lilly and were worth $2,571,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently bought and sold shares of LLY. Iowa State Bank bought a new stake in shares of Eli Lilly and during the second quarter valued at about $104,000. Cribstone Capital Management LLC bought a new stake in shares of Eli Lilly and during the second quarter valued at about $117,000. Physicians Financial Services Inc. increased its stake in shares of Eli Lilly and by 11.2% in the second quarter. Physicians Financial Services Inc. now owns 1,638 shares of the company’s stock valued at $129,000 after buying an additional 165 shares in the last quarter. Orrstown Financial Services Inc. increased its stake in shares of Eli Lilly and by 47.1% in the second quarter. Orrstown Financial Services Inc. now owns 1,874 shares of the company’s stock valued at $148,000 after buying an additional 600 shares in the last quarter. Finally, Jolley Asset Management LLC increased its stake in shares of Eli Lilly and by 52.4% in the second quarter. Jolley Asset Management LLC now owns 2,210 shares of the company’s stock valued at $174,000 after buying an additional 760 shares in the last quarter. Institutional investors own 74.96% of the company’s stock.
Eli Lilly and Co. (NYSE:LLY) traded down 0.21% on Wednesday, reaching $80.71. The company’s stock had a trading volume of 2,467,803 shares. The firm has a market capitalization of $85.37 billion, a PE ratio of 34.79 and a beta of 0.20. The stock’s 50 day moving average is $79.27 and its 200-day moving average is $77.04. Eli Lilly and Co. has a 52 week low of $67.88 and a 52 week high of $88.48.
Eli Lilly and (NYSE:LLY) last posted its quarterly earnings data on Tuesday, July 26th. The company reported $0.86 EPS for the quarter, hitting analysts’ consensus estimates of $0.86. The business had revenue of $5.40 billion for the quarter, compared to analyst estimates of $5.14 billion. Eli Lilly and had a return on equity of 23.99% and a net margin of 11.97%. The firm’s revenue for the quarter was up 8.6% on a year-over-year basis. During the same period in the previous year, the company posted $0.90 earnings per share. Analysts predict that Eli Lilly and Co. will post $3.59 EPS for the current year.
Several analysts have recently issued reports on the company. Leerink Swann restated a “buy” rating on shares of Eli Lilly and in a research report on Sunday, June 26th. Morgan Stanley reiterated a “hold” rating and issued a $88.00 target price on shares of Eli Lilly and in a research note on Saturday, June 4th. Argus upped their target price on Eli Lilly and from $90.00 to $95.00 and gave the company a “buy” rating in a research note on Tuesday, August 2nd. Zacks Investment Research upgraded Eli Lilly and from a “hold” rating to a “buy” rating and set a $93.00 target price for the company in a research note on Friday, July 29th. Finally, BMO Capital Markets reiterated a “buy” rating and issued a $94.00 target price on shares of Eli Lilly and in a research note on Wednesday, July 27th. Two research analysts have rated the stock with a hold rating and nineteen have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $97.16.
In related news, major shareholder Lilly Endowment Inc sold 225,000 shares of Eli Lilly and stock in a transaction dated Thursday, July 7th. The stock was sold at an average price of $79.14, for a total transaction of $17,806,500.00. Following the sale, the insider now directly owns 126,442,509 shares of the company’s stock, valued at $10,006,660,162.26. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Jackson P. Tai bought 5,773 shares of the firm’s stock in a transaction that occurred on Monday, August 15th. The shares were purchased at an average cost of $80.43 per share, for a total transaction of $464,322.39. Following the completion of the transaction, the director now owns 42,306 shares of the company’s stock, valued at $3,402,671.58. The disclosure for this purchase can be found here. 0.20% of the stock is owned by insiders.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Co. (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Co. and related companies with MarketBeat.com's FREE daily email newsletter.